- Hydrocelin is novel investigational injectable device being evaluated for its potential in managing osteoarthritis
- Pivotal clinical trial in osteoarthritis patients on track to start in 2025
Allegro updated this press release on April 20, 2026, to refine certain statements in accordance with regulatory guidelines
Liege, Belgium – 4 March 2025 (08:30 CET) – Allegro NV, a biomedical company developing a transformative nanotechnology-based treatment for degenerative joint disease, announced today that hydrocelin (ALG-001), its lead injectable microparticle hydrogel, has shown a safe biocompatibility profile in three preclinical studies. The studies found no signs of pyrogenicity, irritation or delayed sensitization in the test groups, strengthening hydrocelin’s safety profile after two earlier preclinical studies announced in December. Allegro intends to launch a multi-center pivotal trial in osteoarthritis patients in Belgium later this year.
“These preclinical results are an important step in fulfilling Allegro’s mission of giving back mobility to the millions of people suffering from osteoarthritis around the world. Allegro’s hydrocelin injection, which we expect will need to be administered once a year, is designed to provide rapid pain relief for patients and support healthy joint function. With an ageing population, the need for a lasting solution for osteoarthritis will continue to grow in importance,” said Lucas Decuypere, Chief Executive Officer at Allegro.
Hydrocelin contains cross-linked microparticles acting as tiny shock absorbers in the synovial fluid of the joints. Restoring the shock-absorbing capacity of the synovial fluid reduces pressure, pain relief, and potentially protecting cartilage. In the preclinical studies, Allegro demonstrated hydrocelin was safe to use in three important aspects: the potential to cause irritation following intracutaneous injection, pyrogenicity and delayed sensitization.
Important information
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes”, “estimates,” “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “continue”, “ongoing”, “potential”, “predict”, “project”, “target”, “seek” or “should”, and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The company’s actual results may differ materially from those predicted by the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.